Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis

被引:226
作者
Lisman, T
de Groot, PG
Meijers, JCM
Rosendaal, FR
机构
[1] Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3584 CX Utrecht, Netherlands
[2] Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[4] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands
[5] Leiden Univ, Med Ctr, Haemostasis & Thrombosis Res Ctr, Leiden, Netherlands
关键词
D O I
10.1182/blood-2004-08-3253
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The role of the fibrinolytic system in the development of deep vein thrombosis (DVT) is unclear. We determined the plasma fibrinolytic potential of patients enrolled in the Leiden Thrombophilia Study (LETS), a population-based case-control study on risk factors for DVT. Plasma fibrinolytic potential was determined in 421 patients and 469 control subjects by means of a tissue factor-induced and tissue-type plasminogen activator (tPA)-induced clot lysis assay. Using clot lysis times above the 70th, 80th, 90th, 95th, and 99th percentiles of the values found in control subjects as cutoff levels, we found a dose-dependent increase in risk for DVT in patients with hypofibrinolysis (odds ratios of 1.4, 1.6, 1.9, 2.1, and 2.2, respectively). This indicates a 2-fold increased risk of DVT in subjects with clot lysis times above the 90th percentile. The risk increase was not affected by age or sex (adjusted odds ratio for 90th percentile, 2.0), and after correction for all possible confounders (age, sex, and levels of procoagulant proteins shown to associate with clot lysis times in the control population), the risk estimate was marginally reduced (odds ratio, 1.6 for 90th percentile). Taken together, these results indicate that plasma hypofibrinolysis constitutes a risk factor for venous thrombosis, with a doubling of the risk at clot lysis times that are present in 10% of the population. (C) 2005 by The American Society of Hematology.
引用
收藏
页码:1102 / 1105
页数:4
相关论文
共 28 条
[21]  
Schuster V, 2001, THROMB HAEMOSTASIS, V85, P1004
[22]   Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism [J].
Schutgens, REG ;
Esseboom, EU ;
Snijder, RJ ;
Haas, FJLM ;
Verzijlbergen, F ;
Nieuwenhuis, HK ;
Lisman, T ;
Biesma, DH .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2004, 144 (02) :100-107
[23]   Venous thrombosis after long-haul flights [J].
Schwarz, T ;
Siegert, G ;
Oettler, W ;
Halbritter, K ;
Beyer, J ;
Frommhold, R ;
Gehrisch, S ;
Lenz, F ;
Kuhlisch, E ;
Schroeder, HE ;
Schellong, SM .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (22) :2759-2764
[24]   Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis [J].
van Tilburg, NH ;
Rosendaal, FR ;
Bertina, RM .
BLOOD, 2000, 95 (09) :2855-2859
[25]  
van Wijnen M, 1998, BIOCHEM J, V330, P389
[26]  
vanderMeer FJM, 1997, THROMB HAEMOSTASIS, V78, P631
[27]  
Vlieg AV, 2000, BLOOD, V95, P3678
[28]   Thrombin-mediated activation of Factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis [J].
VondemBorne, PAK ;
Bajzar, L ;
Meijers, JCM ;
Nesheim, ME ;
Bouma, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (10) :2323-2327